Clinicopathological and prognostic values of ErbB receptor family amplification in primary osteosarcoma

References

• Savage SA, Mirabello L. Using epidemiology and genomics to understand osteosarcoma etiology. Sarcoma. 2011;2011:548151.
   PubMedGoogle Scholar
• Bertucci F, Araujo J, Giovannini M. Pancreatic metastasis from osteosarcoma and Ewing sarcoma: literature review. Scand J Gastroenterol. 2013;48(1):4–8.
   PubMed Web of Science ®Google Scholar
• Meyers PA, Gorlick R. Osteosarcoma. Pediatr Clin North Am. 1997;44(4):973–989.
   PubMed Web of Science ®Google Scholar
• Dai X, Ma W, He X, et al. Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing's sarcoma. Med Sci Monit. 2011;17(8):RA177–RA190.
   PubMed Web of Science ®Google Scholar
• Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell. 2014;25(3):282–303.
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127–137.
   PubMed Web of Science ®Google Scholar
• Baker HM, Proft T, Webb PD, et al. Crystallographic and mutational data show that the streptococcal pyrogenic exotoxin J can use a common binding surface for T-cell receptor binding and dimerization. J Biol Chem. 2004;279(37):38571–38576.
   PubMed Web of Science ®Google Scholar
• Marmor MD, Skaria KB, Yarden Y. Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys. 2004;58(3):903–913.
   PubMed Web of Science ®Google Scholar
• Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol. 2006;33(4):369–385.
   PubMed Web of Science ®Google Scholar
• Jorissen RN, Walker F, Pouliot N, et al. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res. 2003;284(1):31–53.
   PubMed Web of Science ®Google Scholar
• Chalela R, Bellosillo B, Curull V, et al. EGFR and KRAS mutations in the non-tumoral lung. Prognosis in patients with adenocarcinoma. J Clin Med. 2019;8:pii: E529.
   Web of Science ®Google Scholar
• Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–1500.
   PubMed Web of Science ®Google Scholar
• De Luca A, Carotenuto A, Rachiglio A, et al. The role of the EGFR signaling in tumor microenvironment. J Cell Physiol. 2008;214(3):559–567.
   PubMed Web of Science ®Google Scholar
• Freeman SS, Allen SW, Ganti R, et al. Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors. Cancer. 2008;113(6):1453–1461.
   PubMed Web of Science ®Google Scholar
• Reese DM, Slamon DJ. HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells. 1997;15(1):1–8.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–182.
   PubMed Web of Science ®Google Scholar
• Di Fiore PP, Pierce JH, Fleming TP, et al. Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell. 1987;51(6):1063–1070.
   PubMed Web of Science ®Google Scholar
• Onda M, Matsuda S, Higaki S, et al. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer. 1996;77(1):71–78.
   PubMed Web of Science ®Google Scholar
• Gorlick R, Huvos AG, Heller G, et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol. 1999;17(9):2781–2788.
   PubMed Web of Science ®Google Scholar
• Akatsuka T, Wada T, Kokai Y, et al. ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer. 2002;94(5):1397–1404.
   PubMed Web of Science ®Google Scholar
• Berghoff AS, Bartsch R, Preusser M, et al. Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients. Breast. 2014;23(5):637–643.
   PubMed Web of Science ®Google Scholar
• Kumagai T, Tomita Y, Nakatsuka SI, et al. HER3 expression is enhanced during progression of lung adenocarcinoma without EGFR mutation from stage 0 to IA1. Thorac Cancer. 2018;9(4):466–471.
   PubMed Web of Science ®Google Scholar
• Jaiswal BS, Kljavin NM, Stawiski EW, et al. Oncogenic ERBB3 mutations in human cancers. Cancer Cell. 2013;23(5):603–617.
   PubMed Web of Science ®Google Scholar
• Ma J, Lyu H, Huang J, et al. Targeting of erbB3 receptor to overcome resistance in cancer treatment. Mol Cancer. 2014;13(1):105.
   PubMed Web of Science ®Google Scholar
• Wang Z. ErbB receptors and cancer. Methods Mol Biol. 2017;1652:3–35.
   PubMedGoogle Scholar
• Kim JY, Jung HH, Do IG, et al. Prognostic value of ERBB4 expression in patients with triple negative breast cancer. BMC Cancer. 2016;16(1):138.
   PubMed Web of Science ®Google Scholar
• Moore C, Parrish JK, Jedlicka P. MiR-193b, downregulated in Ewing sarcoma, targets the ErbB4 oncogene to inhibit anchorage-independent growth. PLoS One. 2017;12(5):e0178028.
   PubMed Web of Science ®Google Scholar
• Zhou W, Wang G, Zhao X, et al. A multiplex qPCR gene dosage assay for rapid genotyping and large-scale population screening for deletional alpha-thalassemia. J Mol Diagn. 2013;15(5):642–651.
   PubMed Web of Science ®Google Scholar
• Baumhoer D, Smida J, Specht K, et al. Aberrant expression of the human epidermal growth factor receptor 2 oncogene is not a common feature in osteosarcoma. Hum Pathol. 2011;42(6):859–866.
   PubMed Web of Science ®Google Scholar
• Liu Y, Ma YH, Sun ZZ, et al. Effect of c-erbB2 overexpression on prognosis in osteosarcoma: evidence from eight studies. Tumor Biol. 2014;35(9):8939–8943.
   PubMedGoogle Scholar
• Siclari VA, Qin L. Targeting the osteosarcoma cancer stem cell. J Orthop Surg Res. 2010;5(1):78.
   PubMed Web of Science ®Google Scholar
• Johansson HJ, Socciarelli F, Vacanti NM, et al. Breast cancer quantitative proteome and proteogenomic landscape. Nat Commun. 2019;10(1):1600.
   PubMed Web of Science ®Google Scholar
• Vuong HG, Tran TTK, Ngo HTT, et al. Prognostic significance of genetic biomarkers in isocitrate dehydrogenase-wild-type lower-grade glioma: the need to further stratify this tumor entity - A meta-analysis. Eur J Neurol. 2019;26(3):379–387.
   PubMed Web of Science ®Google Scholar
• Kim YT, Park SW, Kim JW. Correlation between expression of EGFR and the prognosis of patients with cervical carcinoma. Gynecol Oncol. 2002;87(1):84–89.
   PubMed Web of Science ®Google Scholar
• Maitra A, Wanzer D, Weinberg AG, et al. Amplification of the HER-2/neu oncogene is uncommon in pediatric osteosarcomas. Cancer. 2001;92(3):677–683.
   PubMed Web of Science ®Google Scholar
• Shi F, Telesco SE, Liu Y, et al. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc Natl Acad Sci USA. 2010;107(17):7692–7697.
   PubMed Web of Science ®Google Scholar
• Lee JW, Sung JS, Park YS, et al. Identification of different gene expressions between diffuse- and intestinal-type spheroid-forming gastric cancer cells. Gastric Cancer. 2019;22(5):967–979.
   PubMed Web of Science ®Google Scholar
• Jullien N, Dieudonne FX, Habel N, et al. ErbB3 silencing reduces osteosarcoma cell proliferation and tumor growth in vivo. Gene. 2013;521(1):55–61.
   PubMed Web of Science ®Google Scholar
• Kurppa KJ, Denessiouk K, Johnson MS, et al. Activating ERBB4 mutations in non-small cell lung cancer. Oncogene. 2016;35(10):1283–1291.
   PubMed Web of Science ®Google Scholar
• Mendoza-Naranjo A, El-Naggar A, Wai DH, et al. ERBB4 confers metastatic capacity in Ewing sarcoma. EMBO Mol Med. 2013;5:1087–1102.
   PubMed Web of Science ®Google Scholar
• Dembla V, Groisberg R, Hess K, et al. Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. Sci Rep. 2017;7(1):15963.
   PubMed Web of Science ®Google Scholar
• Wang H, Sun W, Sun M, et al. HER4 promotes cell survival and chemoresistance in osteosarcoma via interaction with NDRG1. Biochim Biophys Acta Mol Basis Dis. 2018;1864(5):1839–1849.
   PubMed Web of Science ®Google Scholar
• Hollmen M, Elenius K. Potential of ErbB4 antibodies for cancer therapy. Future Oncol. 2010;6:37–53.
   PubMed Web of Science ®Google Scholar
• Cassinelli G, Favini E, Dal Bo L, et al. Antitumor efficacy of the heparan sulfate mimic roneparstat (SST0001) against sarcoma models involves multi-target inhibition of receptor tyrosine kinases. Oncotarget. 2016;7(30):47848–47863.
   PubMedGoogle Scholar
• Hughes DP, Thomas DG, Giordano TJ, et al. Essential erbB family phosphorylation in osteosarcoma as a target for CI-1033 inhibition. Pediatr Blood Cancer. 2006;46(5):614–623.
   PubMed Web of Science ®Google Scholar